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The mammalian supraoptic nucleus (SON) is a neuroendocrine center in the brain regulating a variety
of physiological functions. Within the SON, peptidergic magnocellular neurons that project to the
neurohypophysis (posterior pituitary) are involved in controlling osmotic balance, lactation, and
parturition, partly through secretion of signaling peptides such as oxytocin and vasopressin into the
blood. An improved understanding of SON activity and function requires identiﬁcation and characteriza-
tion of the peptides used by the SON. Here, small-volume sample preparation approaches are optimized
for neuropeptidomic studies of isolated SON samples ranging from entire nuclei down to single
magnocellular neurons. Unlike most previous mammalian peptidome studies, tissues are not im-
mediately heated or microwaved. SON samples are obtained from ex vivo brain slice preparations via
tissue punch and the samples processed through sequential steps of peptide extraction. Analyses of
the samples via liquid chromatography mass spectrometry and tandem mass spectrometry result in
the identiﬁcation of 85 peptides, including 20 unique peptides from known prohormones. As the sample
size is further reduced, the depth of peptide coverage decreases; however, even from individually
isolated magnocellular neuroendocrine cells, vasopressin and several other peptides are detected.
Keywords: supraoptic nuclei • peptidome • neuropeptides • peptide processing • prohormone • single
cell • magnocellular neuron • sample preparation • MALDI-MS • ESI-MS/MS
Introduction
Neuropeptides are involved in behavioral, cognitive, and
homeostatic functions throughout the brain and body. Feeding
behavior, circadian rhythms, sleep, learning, and memory are
just a few physiological functions regulated by these biologically
active peptides.
1,2 Neuropeptides are synthesized as larger
protein precursors and undergo a series of processing steps to
produce bioactive neuropeptides. Processing steps include
cleaving the precursor at mono- or dibasic sites, as well as
numerous post-translational modiﬁcations (PTMs) such as
amidation, acetylation, pyroglutamination, and disulﬁde bond
formation.
2-4 Modiﬁcations such as acetylation can be required
for resistance to degradation as well as biological activity.
5
Before the advent of modern mass spectrometry (MS),
neuropeptide characterization was performed by isolating and
sequencing one peptide at a time using N-terminal sequencing
methods such as Edman degradation. After the peptide has
been characterized, appropriate antibodies are created and
quantitative peptide measurements performed using radioim-
munoassay. Although largely effective, one disadvantage of
Edman degradation is that peptides containing N-terminal
PTMs (acetylation, cyclic glutamate or glutamine) cannot be
directly sequenced. Furthermore, the peptide concentration
required for sequencing is typically higher than what is required
for MS structural characterization.
Recent developments in sample separation and MS analysis
have improved identiﬁcation and characterization of peptides
from biological samples ranging from brain structures
6-12 to
single cells.
13-17 When analyzing complex systems such as the
mammalian brain, MS has been restricted to relatively large
morphological structures: as examples, an entire hypothalamus,
striatum, or hippocampus.
6-10 In many cases, obtaining ad-
equate amounts of analyte requires large sample sizes or
working with high concentration peptides from neuroendocrine
structures such as the pituitary that have signiﬁcant amounts
of peptides.
18 Postmortem degradation also becomes an issue
due to proteolytic enzymes present in sample tissues.
19,20 To
improve sampling efﬁcacy, enzyme deactivation has received
recent attention, with studies using a variety of techniques that
include using preservatives such as dihydroxybenzoic acid
(DHB),
12 focused microwave irradiation before decapita-
tion
10,11,21,22 or microwave irradiation after decapitation,
7,20 or
boiling the tissue immediately after decapitation.
9 The effects
of protein degradation on rodent tissue have been studied using
MS-based approaches.
7,9,20 For instance, Che and colleagues
7
found variations in the levels of some hypothalamic peptides
when a 20-s delay was introduced between decapitation and
microwaving, and Sko ¨ld and co-workers
20 showed that detect-
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Published on Web 09/25/2008able neuropeptide levels greatly decreased when the time
between animal sacriﬁce and microwaving was as brief as 1
min. Moreover, levels continued to decrease during longer
delays.
Although data demonstrating the effectiveness of microwave
treatment in preventing peptide degradation makes inherent
sense and the research is certainly of high quality, it is also
surprising when considering the large body of literature on ex
vivo brain slice experiments. The brain slice preparation is a
well-established technique used in studies investigating mech-
anisms of circadian rhythmicity, learning, neuronal repair, and
synaptic plasticity. Typically, brain slices are kept functional
for more than 24 h ex vivo.
23-25 Furthermore, it has been shown
that altered neurosecretory vesicle pools and other cell or-
ganelles recover and stay constant for hours following brain
slice preparation.
25,26 Advantages of the method include the
ability to combine functional tests of peptide release with
peptidome measurements,
27 and to clearly delineate small,
anatomically deﬁned brain structures such as individual brain
nuclei from fresh (non heat-treated or microwaved) samples.
Here, we test the ability to isolate peptides using the
established physiological preparation of the fresh brain slice.
We combine the aforementioned protocols for peptidomic
studies of the brain with a speciﬁc focus on the supraoptic
nucleus (SON). Although the SON has been intensively
studied,
28-38 this may be the ﬁrst mammalian neuropeptidom-
ics examination of this small, functionally and morphologically
deﬁned cluster of cells by means of mass spectrometry. In
addition to the characteristic products of the SON, oxytocin,
and Arg-vasopressin, there are many SON-derived peptides
colocalized within this nucleus, presumably at lower levels. In
situ hybridization, and immunohistochemical and MS studies
have reported several bioactive peptides in the SON coming
from different precursors such as secretogranin II,
39 chromog-
ranin A,
40 cocaine- and amphetamine-regulated transcript
(CART),
41,42 and neuropeptide Y.
43 However, we speculate that
these peptides are a subset of the total peptides present in the
SON.
Because of its physiological importance, abundance of
neuropeptides, and easy isolation, we identify and characterize
the SON peptidome. In analyses using liquid chromatography
(LC) electrospray ionization (ESI) tandem MS (MS/MS) as well
as LC matrix-assisted laser desorption/ionization (MALDI) MS/
MS, we identify 85 peptides, a majority of which correspond
to known or previously characterized peptides.
7-10 Moreover,
20 peptides have been unambiguously identiﬁed with MS/MS
and appear not to have been reported previously.
In addition, we examined selected sections of the SON. In
mammals, the hypothalamic-neurohypophysial system con-
tains populations of well-deﬁned neurosecretory cells produc-
ing cell-to-cell signaling peptides that participate in a variety
of peripheral regulatory mechanisms. These cells, the magno-
cellular neurons (MCNs) of the SON, are part of the hypotha-
lamic neuroendocrine system. They are relatively large for
mammalian neurons (∼30 µm in diameter) and produce
signiﬁcant amounts of neuropeptides, which are released into
the circulatory system. Interestingly, MCNs appear to release
their peptides dendritically,
44,45 making them an interesting
target for cellular, and potentially even subcellular, studies on
dense core vesicle targeting and release.
Can we adapt single cell MS to interrogate individual MCNs?
Because of its high sensitivity and salt tolerance, MALDI MS
allows analysis not only of the peptidome of a neural tissue
extract, but also of a single cell.
13-17 Investigation of an
individual neuron using single-cell MALDI MS enables iden-
tiﬁcation of peptides processed from the same precursor, and
also determination of colocalized neuropeptides from different
precursors. Jimenez et al.
14 used ∼100-µm diameter molluscan
neurons to mass ﬁngerprint the neuropeptides, and several
have worked with smaller, ∼20-µm insect neurons.
15,46,47 More
recently, Rubakhin et al.
16,17 successfully performed MALDI MS
on individual 8-10-µm diameter mammalian pituitary cells and
characterized a number of pro-opiomelanocortin (POMC) and
CART-related peptides. We proﬁle a single MCN with MALDI,
without introducing exogenous labels or enzymatic treatments,
in order to characterize peptide precursors and their products
found within this cell population.
Experimental Section
Chemicals. All reagents were obtained from Sigma-Aldrich
Chemical Co. (St. Louis, MO), unless otherwise noted. Water
was prepared by a Milli-Q ﬁltration system (Millipore, Bedford,
MA). The peptides standards used for external calibration were
provided by Bruker Daltonics, Inc. (Billerica, MA).
Animal Sacriﬁce and Brain Slice Treatments. The animals
and sacriﬁce procedures used are delineated in greater detail
elsewhere.
48 Brieﬂy, 6-12 week old Long-Evans/BluGill male
and female rats (University of Illinois at Urbana-Champaign)
were sacriﬁced by decapitation in accordance with protocols
established by the University of Illinois Institutional Animal
Care and Use Committee and in accordance with all state and
federal regulations. The brain was quickly removed and the
hypothalamic coronal brain slices (500 µm) containing the
paired SON were prepared as previously reported.
23 Slices were
maintained in Earle’s balanced salt solution, pH 7.2, at 37 °C
supplemented with 24.6 mM glucose, 26.2 mM sodium bicar-
bonate, and 5 mg/L gentamicin and saturated with 95% O2-5%
CO2. Brain slices were transferred to physiological phosphate
buffered saline (PBS) and the SON (∼1m m
3 of brain tissue)
was removed from the ex vivo coronal brain slice by punching
a 1-mm plug or cutting out the nucleus on the surface of a
plastic Petri dish placed on a bed of ice. Because the SON is
situated directly adjacent to the optic tracts, these structures
served as easily identiﬁable landmarks for SON collection.
These samples may include small amounts of tissue from the
nearby optic tract. After the SON punches were collected, the
PBS was removed and the tissue processed for peptide
extraction.
Multistage Peptide Extraction. SONs from both hemispheres
from 12–17 animals were pooled and collected in 1.5-mL plastic
vials. To increase the number of peptides extracted and
eventually detected with MS, tissue extraction was performed
in multiple stages with each experiment repeated at least three
times. During the ﬁrst stage of peptide extraction, 300 µLo f
sterile deionized (DI) water (MilliQ), preheated to 90 °C, was
added to the SON tissue samples, capped, and placed into a
boiling water bath for 10 min. Next, the samples were centri-
fuged (Mini Centrifuge, model C1301, Denville, Woodbridge,
NJ), the supernatant was transferred to a new vial, and the
resulting pellets were frozen at -80 °C until the second stage
of extraction. The second stage extraction was processed using
300 µL of acidiﬁed acetone (40:6:1 acetone/water/HCl) for 1 h
at 4 °C. The sample was vortexed for 1 min and centrifuged at
14 000 rpm for 5 min, and the supernatant was collected. The
third extraction stage used 300 µL of 0.25% acetic acid and
followed the same sample processing as stage two. All extracts
Signaling Peptides in the SON research articles
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San Jose, CA) and reconstituted with 10 µL of solvent A
(aqueous 5% acetonitrile (ACN) containing 0.1% formic acid
(FA) and 0.01% triﬂuoroacetic acid (TFA). After reconstitution,
the three samples were pooled and ﬁltered through a 10 kDa
molecular weight cutoff tube (Millipore) (see Supporting
Information, Figure S1).
Liquid Chromatography-Mass Spectrometry (LC-MS). Chro-
matographic separation of the extracted peptides and mass
spectrometric analyses were performed using a capLC (Micro-
mass, U.K.) LC system coupled with an HCT Ultra-PTM
Discovery system ion-trap mass spectrometer (Bruker Dalton-
ics) equipped with an electrospray ionization source. For LC-
MALDI-time-of-ﬂight (TOF/TOF)-MS analysis, the capLC was
coupled with a robotic fraction spotter (ProteineerFC, Bruker
Daltonics). The samples were loaded onto a trap column
(PepMap, C18, 5 µm, 100 Å, Dionex, Sunnyvale, CA) using a
manual injector (Valco Instruments Co., Inc., Houston, TX) and
washed for 5 min. The trapped peptides were then eluted in
reverse direction onto a reverse phase capillary column (LC
Packings, 300-µm inner diameter × 15 cm, C18 PepMap100,
100 Å) using a solvent gradient at 2 µL/min ﬂow rate. The
solvent gradient was generated using solvent A and solvent B
(aqueous 95% ACN containing 0.1% FA and 0.01%TFA). The
70-min gradient run for LC separation included three steps:
5-80% solvent B in 15-55 min (linear); 80% solvent B for
55-60 min (isocratic); 80-5% solvent B in 60-65 min (linear).
The MS data acquisition and the subsequent MS/MS of
selected analytes were performed in a data-dependent manner
using the Esquire software (Bruker Daltonics). For each MS
scan, three peptides were selected to be fragmented, for
300-500 ms, based on their charge (preferably +2) and
intensity. Dynamic exclusion of previously fragmented precur-
sor ions was set to 2 spectra for a period of 60 s. The MS and
MS/MS scans were performed in the range of m/z 300-1500
and 50-2000, respectively.
For LC-MALDI-TOF/TOF-MS analysis, chromatographic sepa-
ration was performed using a 45-min gradient run comprising
the following parameters: 5-80% solvent B in 10-30 min
(linear); 80% solvent B for 30-35 min (isocratic); 80-5% solvent
Bi n3 5 -45 min (linear). The chromatographic elutant was
monitored using a UV detector (Waters, Milford, MA) and
subsequently spotted onto a ground steel MALDI sample plate
at the rate of 60 s/spot using ProteineerFC. Immediately after
spotting, 1 µLo fR-cyano-4-hydroxy cinnamic acid matrix was
applied to each spot.
For LC-Fourier transform (FT) MS analysis, separations were
accomplished using a ProteoPep II C18 column from New
Objective (Woburn, MA), with an inner diameter of 75 µm and
length of 10 cm. The chromatographic gradient was performed
using a 1D NanoLC pump from Eksigent Technologies (Dublin,
CA) operating at 300 nL/min with the following gradient
parameters: 10% solvent B for 0-10 min (isocratic); 10-30%
solvent B for 10-20 min (linear); 30-100% solvent B for 20-80
min (linear); 80-5% solvent B for 80-100 min (linear). Peptides
were detected ona7Tlinear trap quadrupole (LTQ)-FT
instrument from Thermo Scientiﬁc, and a setting of 15 V was
used for mild ion activation in the ESI source. The LTQ-FTMS
method consisted of three scan events, all in proﬁle mode with
four microscans used per full scan. An initial, full scan event
was performed at a high resolution (100 000) in FT mode. The
second scan event was a data-dependent collision-activated
dissociation (CAD) MS/MS scan of the most abundant peak in
the previous full scan, again with FT mode detection (50 000
resolution). MS/MS settings were as follows: isolation width )
4 m/z; minimum signal threshold ) 50 000 counts; normalized
collision energy (NCE) ) 40%; duration ) 200 ms, and q-factor
) 0.5. Dynamic exclusion was used for a duration of 6 min per
precursor to avoid redundant fragmentation data sets. The third
scan was a full scan detected in the ion trap (low resolution).
All neuropeptide identiﬁcations for this system were ac-
complished using ProSightPC software (Thermo Scientiﬁc) as
described below. The intact and CAD fragmentation data were
used to search a database of predicted neuropeptides.
Matrix Assisted Laser Desorption/Ionization Time-of-Flight
Mass Spectrometry (MALDI TOF/TOF MS). Each sample spot
was analyzed by a Bruker Ultraﬂex II TOF/TOF instrument with
a delayed ion extraction and a frequency tripled Nd:YAG laser
operating at 1064 nm and 50 Hz (Bruker Daltonics). Mass
spectra were accumulated over 2 to 3 individual acquisitions
of 300 laser shots each. Intense peaks from the MS scan of
samples were manually analyzed and selected for further
analysis using the MS/MS feature of the Ultraﬂex II instrument.
Several peaks were assigned based on accurate mass matches
without MS/MS data, normally with the conﬁdence of these
assignments enhanced by the detection of other related pep-
tides from the same prohormone.
Single Cell Analysis. Individual SON neurons and small
groups of cells were isolated in accordance with the detailed
protocol described previously.
17 Brieﬂy, brain sections were
immersed in solution containing 33% glycerol and 67% of
modiﬁed Gey’s balanced salt solution (mGBSS, in mM, 1.5
CaCl2, 4.9 KCl, 0.2 KH2PO4, 11 MgCl2, 0.3 MgSO4, 138 NaCl,
27.7 NaHCO3, 0.8 Na2HPO4, 25 HEPES and 10 glucose, pH 7.2)
and kept in this solution during all isolation steps. Addition of
glycerol stabilizes cellular structures during tissue and cell
manipulation as well as prevents dehydration of the specimen.
Small, several-hundred micrometers in diameter, regions of the
SON were removed from the slices and placed on a glass slide
positioned on an inverted light microscope (see Figure 3A).
Under visual control, ﬁne-tipped glass needles were used to
isolate, pick up, and transfer individual neurons and small
groups of cells onto a metal MALDI sample plate. Pipettes
pulled from borosilicate glass were used to deposit MALDI
matrix-saturated DHB in water onto specimens.
Data Analysis. Tandem MS data obtained from the ESI-MS/
MS and MALDI-TOF/TOF systems were selected and exported
to the Biotools software program (Bruker Daltonics) for further
analysis. The data were converted to a Mascot (Matrix Science,
London, U.K.) generic ﬁle format and searched against mouse
and rat IPI databases using Peaks software (Bioinformatics
Solutions, Inc., Waterloo, CA). Search parameters for the Peaks
software included unsuspected cleavage site, N-terminal pyro-
glutamic acid, and C-terminal amidation. Subsequently, the
search results were conﬁrmed by manual de novo analysis using
the Data Analysis software (Bruker Daltonics). Complimentary
searches were also performed with Mascot using the MSDB
database and an in-house database of neuropeptide prohor-
mones. Parameters for the Mascot search included enzyme
speciﬁed as “none,” and variable modiﬁcations were consid-
ered, such as acetylation of N-terminal, amidation of C-
terminal, pyro-Glu of Q and pyro-Glu of E. The peptide mass
tolerance for MS/MS data was set at 0.5 Da. The MS/MS data
were manually veriﬁed to contain at least three consecutive
amino acid fragment ions for conﬁrming positive identiﬁcation
of a peptide. In addition, MALDI MS data were analyzed by
research articles Bora et al.
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putative neuropeptides to the NeuroPred prediction engine
(http://neuroproteomics.scs.uiuc.edu/neuropred.html)
49,50 us-
ing an in-house-generated database of known rat prohormones.
Mass matches within 150 ppm were required for positive
identiﬁcations.
Analysis of FTMS Data. Data ﬁles (*.raw) were reduced to a
ProSightPC Upload Format ﬁle (*.puf) using an in-house
program (cRAWler), which groups MS/MS data from all precur-
sors of the same protein into one experiment. An experiment
consisted of one precursor mass and all fragment ion masses
derived from it. Within this program, molecular weights of
precursor and product ions were also determined using a highly
modiﬁed THRASH algorithm.
51 Fragment ions for all MS/MS
scans were required to have an S/N ratio of 5:1 or greater to
be considered for database searching. Each *.puf ﬁle typically
contained hundreds of experiments from a single LC-FTMS run.
The experiments within these ﬁles were then searched against
two types of databases using ProSightPC
52,53 (Thermo Scien-
tiﬁc) and/or neuroProsight (http://neuroprosight.scs.uiuc.
edu/), a highly annotated mouse proteome database of intact
proteins, and a database of predicted mouse neuropeptides
generated by the NeuroPred tool described above. Two types
of searches were performed against these databases. First, an
Absolute Mass search was done to ﬁnd any proteins/peptides
that were identiﬁed as they appeared in the database. Second,
a Biomarker search was done to retrieve any endogenously
cleaved pieces of proteins/peptides in the databases. In all
cases, the mass tolerance for fragment ions was (5 ppm. All
retrieved proteins and peptides needed to meet two require-
ments to be considered a positive identiﬁcation: (1) an expect
score of less than 10
-5 and, (2) no unexplained mass shifts
between the observed and theoretical intact masses.
54 Identi-
ﬁcations that could not be assigned unambiguously were
validated using the Sequence Gazer tool to account for errors
in determination of the monoisotopic mass of the protein.
Results
Peptidomics studies provide detail on the peptides present
in entire brains to selected brain regions. This study represents
a downscaling of sample sizes for mammalian neuropepti-
domics analysis to the level of an identiﬁed nucleus, here the
hypothalamic SON. In comparison with previous neuropepti-
domics methods devised for larger brain regions, our analyses
show a comparable number of peptide identiﬁcations. Because
the ability to work with select, anatomically well-deﬁned nuclei
requires precise registration of the samples, it is easier to work
with intact brain slices than heat-treated or microwaved tissue,
especially as the anatomical features required for identiﬁcation
of the region may be altered by such treatments.
7,20
One question of particular interest was whether or not
neuropeptides would be detected in such samples, given that
prior work showed a large reduction in neuropeptide levels and
an increase in peptide fragments from proteins shortly after
decapitation.
11,21 Our results demonstrate that, even if peptides
are released and degraded immediately after death, the neu-
rosecretory vesicles and peptide levels recover. After sampling
the SON by tissue punch from a brain slice, the sample is
denatured using heat. Increasing sample temperature by heat-
ing with 90 °C DI water reduces protease activity and serves as
an extraction solution. We see almost no difference between
extracting peptides using DI water extraction and an acidiﬁed
acetone extraction (Supporting Information, Figure S1); how-
ever, fewer peaks were seen in the acetic acid extraction.
Although there is variation in the data between extraction
solutions, each approach produced reproducible mass spectra.
Because some peptides are extracted more efﬁciently using
different conditions, our ﬁnal method involves treating the SON
tissue with a sequential series of solvent extractions. By
increasing the tissue temperature in water, followed by two-
stage extraction using acidiﬁed acetone and acetic acid, we
achieve an increased recovery of the SON peptidome.
Using this optimized approach, we detect 20 peptides
characterized using MS/MS that were not reported in prior
hypothalamus peptidome studies (Table 1). The quality of mass
spectra (Supporting Information, Figure S1) and the number
of products detected (Supporting Information, Table S1) indi-
cate that the peptides are not affected by the lack of immediate
microwaving and the delay between slice preparation and
sample extraction.
Here, we characterized and identiﬁed 85 peptides, many of
which include peptides derived from known prohormones (see
Tables 1 and 2). Che et al.
7 reported 41 neuropeptides from
three brain regions (hypothalamus, hippocampus, and stria-
tum) using a quadrupole time-of-ﬂight mass spectrometer
equipped with a capillary/nano-LC system. Dowell and co-
workers
9 detected 56 neuropeptides from the rat hypothalamus
and striatum using a different extraction protocol and 1D LC-
MS/MS, 2D LC-MS/MS, and MALDI-FTMS. Our approach uses
a smaller brain region from ex vivo brain slices and multistage
extraction protocols along with LC-MALDI MS, LC-ESI MS, and
LC-ESI FTMS, resulting in the identiﬁcation of several unre-
ported peptides. The results are consistent with previous
studies that characterized peptides in larger brain regions
discussed above.
The use of multiple MS-based platforms, LC-MALDI MS, LC-
ESI MS, and LC-ESI FTMS, enhances peptide and protein
coverage as each platform excels at speciﬁc types of samples
and analytes. Therefore, their combination facilitates detection
of larger numbers of peptides from the SON samples. A
majority of detected peptides have been previously observed
and characterized in different parts of the mammalian brain
such as the hypothalamus, striatum, pituitary, and hippocampus.
Our data enhances prior peptidome studies on the hypo-
thalamus and striatum.
9 As previously reported peptides from
these regions, we also observe the provasopressin[24-32]
(AVP), the pyro-Glu form of CART (Figure 1A),
10 POMC[124-136]
(melanotropin alpha),
7,9 somatostatin[103-116] (somatostatin
14), somatostatin[89-100],
7,9 proenkephalin A[100-104] (met-
enkephalin), proenkephalin A[219-229], proenkephalin A[198-
209],
7,9 secretogranin 1[585-594],
9 proSAAS[245-260] (big
LEN), proSAAS[42-59] (little SAAS)
7,9 and proMCH[131-143].
9
Figure 1 shows the MS/MS fragmentation spectra of the known
peptides CART[28-36] (Figure 1A) and provasopressin[154-168]
(Figure 1B) identiﬁed in the SON, with Figure 2 showing MS/
MS results from two MS platforms. In addition to products from
known prohormones, several different protein fragments have
been identiﬁed in this analysis, most of which correspond to
pieces of myelin basic protein (MBP), the second most abun-
dant protein in the brain (Table 2).
55
Twenty novel peptides (Table 1) are identiﬁed using MS/
MS from various precursors: provasopressin, somatostatin,
secretogranin 1, secretogranin 3, proenkephalin B, cortistatin,
somatotropin, proSAAS, and neurotensin. Figure 1B shows an
example of the tandem MS (MS/MS) fragmentation spectra for
a novel peptide derived from provasopressin. This peptide
Signaling Peptides in the SON research articles
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tial product of Leu-X speciﬁc protease.
7 A majority of se-
quenced peptides in the SON are generated by enzymatic
cleavage of mono- or dibasic sites of the corresponding
prohormones. However, in several cases of the newly discov-
ered peptides, the prohormone cleavage occurs at uncommon
processing sites: C-terminus of provasopressin, somatostatin,
N-terminus of secretogranin I, N-terminus of secretogranin III,
N-terminus signal peptide of cortistatin, N-terminus of proen-
kephalin B, proSAAS (Table 1). The possibility that these
cleavages occur due to extracellular peptide degradation in situ
cannot be ruled out.
The peptidome of the SON is as complex as the previously
reported peptidome of the entire hypothalamus. At what stage
of sample reduction does the peptide complement simplify?
To investigate the peptidome of even smaller samples, indi-
vidual MCN were manually isolatedswithout enzymatic treat-
ment or in vivo or in vitro labeling of the SONsusing coronal
brain slices stabilized with glycerol (Figure 3A). Here, MALDI
MS of a small group of MCNs provides a cleaner spectrum as
compared with the mass proﬁle of single cells, which is not
surprising considering the signiﬁcant increase in the amount
of peptides available for analysis. Using MS measurements, AVP
(m/z 1083.45) can be unambiguously identiﬁed in a low mass
range (Figure 3) and neurophysin II (m/z 9842.29) was identi-
ﬁed in the higher mass range (Supporting Information, Figure
S2), corroborating previous reports of neurophysin prohor-
mones being present in MCN neurons. Different peaks are
visible in the higher range mass spectra (Supporting Informa-
tion). Because the amount of material in an individual cell is
too small for MS/MS approaches, we assign these peaks based
on sequenced peaks from the SON study and the mass match
within the individual MCN. Interestingly, using such mass
matching, we identiﬁed a CART-related peptide, CART[28-36]
(Figure 3B). Many peaks were unidentiﬁable due to the low
amount found in a single cell. Reduction of sample size to the
single cell level reduces the depth of peptide coverage but
provides a more streamlined linkage of functional, morphologi-
cal and biochemical information.
Discussion
For the current neuropeptidome study of the SON, hypo-
thalamic coronal brain slices kept in an oxygenated media are
used and a complement of peptides detected. How can this
be reconciled with prior work showing that tissue denaturation
immediately after animal death is required, or large-scale
protein and peptide degradation is observed?
7,20 The prior
peptidome comparisons have been between tissue that is heat-
or microwave-treated with various time delays, and not with
living brain slices. In fact, peptide-containing dense core
vesicles of neurosecretory cells in brain slices lose a fraction
of their content initially; however, the contents recover and stay
constant for at least 9 h, as shown by Hatton et al.
25 Further-
more, it has been well-established that living brain slices can
be used to successfully study the suprachiasmatic nucleus
(SCN), the master biological clock. In this case, the experiments
demand the maintenance of active tissue for longer than
24 h.
23,48 Similarly, Chen et al.
56 found that pituitary adenylate
cyclase activating peptide (PACAP) remained active in SCN
brain slices longer than 19 h in continuously perfused cham-
bers. On the basis of these studies, and with the information
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4998 Journal of Proteome Research • Vol. 7, No. 11, 2008in prior peptidome studies,
6-9 we infer that the releasable pool
of peptides is rapidly depleted but recovers before the SON is
isolated.
Once the SON punch is made and the tissue is removed from
the chamber, degradation will occur; we stop this process by
using a hot water treatment that also serves to facilitate the
peptide extraction processes. After protease deactivation, we
employ acidic extraction to complete the peptide extraction.
Comparison of the number of characterized SON peptides with
the number of identiﬁed peptides reported for larger brain
structures
6-9 supports the efﬁciency of our strategy.
We used a combination of mass spectrometric approaches
(LC-MALDI, LC-ESI, and LC-ESI-FTMS) to increase the cover-
age in this proteomics investigation and unambiguously iden-
tify the peptides. Each approach has its advantages, excelling
at characterizing different peptides and modiﬁcations. For
example, LC-FTMS/MS is a great tool for unambiguously
identifying peptides through high-resolution measurements of
precursor and product ions. The major drawback to this
technique is the lower sensitivity inherent to FT-ICR mass
spectrometry. Thus, it is a great tool for making peptide
assignments when the ions signals are sufﬁcient, but it trails
other techniques in terms of the number of peptides identiﬁed.
The detected peptides are the result of processing of known
prohormones, with these processing steps either being intra-
cellular (before peptide release) or extracellular (after peptide
release), the latter possibly being the result of degradation
during sample preparation. A number of detected peptides
originate from unconventional cleavage sites, which may be
due to extracellular enzymes. In the case of interleukin-
3[54-62], the removal of the C-terminal Asp residue may be
due to the acidic extraction.
7,9 Peptides originating from
provasopressin precursor indicate that multiple unconven-
tional, nonspeciﬁc cleavages may occur either during the acidic
extraction or through enzymatic processing. Because it is
difﬁcult to directly relate peak heights of structurally distinct
peptides to the amount of peptide present (at least without
using calibration standards), it is difﬁcult to know whether
some of these unusually processed peptides are present at trace
levels compared to the known biologically active peptides.
Surprisingly, one peptide that we did not detect is oxytocin,
even though it is in an ideal mass range (m/z 1006.44) for
characterization. It should be noted that, when the entire
hypothalamus was extracted, oxytocin was not reported in at
least one prior study.
9 Nevertheless, there are reports of
oxytocin in the hypothalamus identiﬁed by mass
6 as well as
following N-terminal modiﬁcation.
8 Considering that 90% of
the content in the SON peptides is released dendritically and
not somatically or axonally, oxytocin is expected in the SON.
Two novel peptides, cortistatin [20-33], and provaso-
Figure 1. MALDI-TOF/TOF (MS/MS) data allows the identiﬁcation of several peptides in the SON sample: (A) CART[28-36],
A.pQEDAELQPR.A, m/z 1067.52 (which was previously characterized in a mouse brain sample); (B) a novel peptide from the vasopressin
prohormone: provasopressin[154-168] L.AGTQESVDSAKPRVY, m/z 1606.69.
Signaling Peptides in the SON research articles
Journal of Proteome Research • Vol. 7, No. 11, 2008 4999pressin[154-168], and a previously characterized peptide,
provasopressin[151-168], have Leu-X or Leu-Leu cleavage
sites. Che et al.
7 assumed the presence of a Leu-speciﬁc enzyme
in the processing of corticotropin-like intermediary peptide of
POMC prohormone, and Hummon et al.
57 reported Leu-Leu
cleavage sites in Aplysia californica prohormones. It is known
that in vertebrates, the enzyme renin speciﬁcally cleaves
Leu-Leu sites.
58 Another enzyme, chymotrypsin, previously
characterized in the human, rat, and pig, cleaves Leu-Ala
sites.
59 On the basis of these studies, we assume that cortista-
tin[20-33] and provasopressin[154-168] are cleaved by either
rennin-like or chymotrypsin-like enzymes. We further speculate
that provasopressin[151-168] and provasopressin[154-168] are
processed in intracellular secretory vesicles since they also were
observed in prior microwaved samples (data not shown).
According to Che et al.,
7 rapid microwave irradiation before
decapitation prevents vesicle fusion and neuropeptide release;
hence, the peptides remain in secretory vesicles and are
available for extraction.
MS/MS is capable of characterizing the PTMs present in
neuropeptides, which is important as these PTMs often directly
modify the activity or lifetime of the peptide. The most
common PTMs in mammalian tissues are N-terminal acetyla-
tion and C-terminal amidation.
2 In 1987, Fischer and Spiess
60
identiﬁed a glutaminyl cyclase converting enzyme in mam-
malian brain responsible for the formation of N-terminal pyro-
Glu. Additionally, in situ and immunocytochemical studies
showed that the SON contains a glutaminyl cyclase-converting
enzymerequiredtocreatepyro-Gluformsofseveralpeptides.
60,61
Here, we detect pyro-Glu forms of CART[28-36],
10 neurotensin
precursor[150-164], and progonadoliberin I precursor[24-33].
We also detect amidation of AVP, substance P,
62
POMC[103-120],
7 and POMC[124-136],
62 as shown in Table
1. We also identify novel N-terminal acetylated peptides such
as proenkephalin[198-209], POMC[124-137], secretogranin
2[287-297], secretogranin 5[198-210], secretogranin 5[180-195],
the pyro-Glu forms of secretogranin 1[597-611], proenkephalin
B[228-248], and neurotensin precursor[150-162] (Table 1).
Although our processing steps reduce protein degradation, we
did detect several peptides from proteins that are not prohor-
mones (Table 2). MBP is the second most abundant protein in
the central nervous system and is present in the peripheral
nervous system as well.
55 MBP can have different PTMs such
as phosphorylation of serine and threonine residues, deami-
dation of Asn or Gln, citrullination and methylation of arginine
residues, and N-terminal acetylation of Thr residues.
63-66 MBP
Figure 2. Sequencing of known peptides from somatostatin; somatostatin[89-100] R.SANSNPAMAPRE.R, m/z 1243.56, using two tandem
MS approaches: (A) MALDI-TOF/TOF and (B) LC-ESI ion trap.
research articles Bora et al.
5000 Journal of Proteome Research • Vol. 7, No. 11, 2008plays an important function in axon myelination, but other
possible roles of MBP are hinted, such as signiﬁcant changes
in mRNA levels on exposure to cocaine.
67,68 Three peptides
derived from MBP are detected in the current study of the SON
peptidome, one of which exhibits N-terminal acetylation of Thr
residues (Table 2).
Our neuropeptidomics study of this small nucleus extends
to the single cell level using MALDI MS. Although in SON
extracts we are able to identify several fragments derived from
provasopressin, our single cell experiments detect the charac-
teristic peptides processed from this hormone. The major
drawback of single cell MS is the low amount of material
available for analysis; some peptides are often present below
the detection level of the employed MS approach. Because of
our careful isolation approach, extracellular degradation prod-
ucts from peptides and proteins are not normally detected.
Thus, our detection of CART-related peptide in a portion of
the studied MCN cells is exciting and suggests that we are
observing cell-to-cell differences in the peptide complement
in a “homogenous” population of MCNs.
With the ability to perform peptidome studies in well-
deﬁned, smaller anatomical regions from the brain slice,
coupled with novel methods of characterizing stimulation-
dependent peptide release recently reported,
27 the ability to
link peptide complement to function has become possible.
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